Methods are disclosed of treating diabetes, abnormal adipocyte activity, andinsulin resistance using C-terminalfragments of adiponectin receptor R1. Methods of causing the secretion ofinsulin in healthy and diabetic patients using C-terminalfragments of adiponectin receptor R1 are also disclosed. In addition, methodsare disclosed of increasing the insulin levels in healthypatients using C-terminal fragments of adiponectin receptor R1. In addition,methods of treating abnormal adipocyte activity, treatingmetabolic syndrome, causing insulin secretion, increasing insulin levels,inhibiting insulin degradation enzyme, treating Alzheimer'sdisease, treating cardiovascular disease associated with adiponectin levels,inhibiting ADAM- 17 enzyme, treating a conditionassociated with TNF-alpha, and treating a condition associated with HER2- neuare disclosed. Compositions, dosage forms, and kitsare also disclosed.
